Press "Enter" to skip to content

A green light for the use of Johnson Johnson vaccine in the EU


The decision is expected to be approved and approved by the EU Commission in a short time. Johnson and Johnson’s vaccine will be the fourth Covid-19 vaccine approved in the EU.

In the statement made by EMA, it was stated that in the light of the data obtained, the vaccine was effective and safe and could be used by EU countries.

It was announced that Johnson and Johnson’s single-dose Covid-19 vaccine, which was tested on 44 thousand people in the USA, South Africa and Latin American countries, was 67 percent effective and provided strong protection against disease and death. The vaccine was approved for use in the USA on February 28, and vaccine distribution started on March 1.

Johnson and Johnson vaccine is used as a single dose and can be stored in the refrigerator for up to 3 months.

In the EU, BioNTech-Pfizer, Moderna and AstraZeneca vaccines were previously approved for use. The preliminary evaluation process of the vaccines of Novavax and Curevac companies and Russia’s Sputnik V vaccine continues. No application for use approval has yet been made for these vaccines.

The EU has so far, including options, to purchase 600 million doses of vaccine with BioNTech-Pfizer, 400 million with AstraZeneca, 300 million with Sanofi-GSK, 400 million with Johnson and Johnson, 405 million with CureVac, and 460 million with Moderna. .

It is stated that Johnson and Johnson may begin the delivery of vaccines to the EU in mid-April at the earliest.


Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *